Avancerad sökning
Visar resultat 1 - 5 av 16 avhandlingar som matchar ovanstående sökkriterier.
1. Monitoring of neuroendocrine tumor patients undergoing systemic therapies
Sammanfattning : Monitoring of neuroendocrine tumor (NET) patients undergoing systemic therapies is troublesome as biomarkers capable of detecting tumor responses have been difficult to establish. Changes in the sum of target lesion diameters are used to evaluate the effects of therapy according to the response evaluation criteria in solid tumors (RECIST 1.1). LÄS MER
2. Theranostics in Neuroendocrine Tumors : Somatostatin Receptor Imaging and Therapy
Sammanfattning : Neuroendocrine tumors (NETs) are characterized by cellular overexpression of somatostatin receptors (SSTR), which allows for the use of radiolabeled somatostatin analogs (SSA) for both imaging and therapy. Because NETs often are diagnosed at a metastatic stage, curative surgery is not possible. LÄS MER
3. Nuclear medicine imaging and treatment in pheochromocytoma, paraganglioma, and role of the new tracer 11C-hydroxy ephedrine in diabetes mellitus
Sammanfattning : Carbon-11 hydroxy ephedrine (11C-HED) is a norepinephrine analog which binds to the norepinephrine receptor present in adrenal medulla, lung, liver and pancreas. 11C-HED-positron emission tomography with concomitant computed tomography (PET/CT) can image these organs. LÄS MER
4. Small-scale dosimetry methods for normal tissues after radioembolization and peptide receptor radiotherapies; a focus on the liver parenchyma and the bone marrow
Sammanfattning : Radionuclide therapies are increasingly used in cancer treatments as they have been proven to be both effective and safe. As biodistributions and uptake vary widely between patients, a standardized approach is bound to leave a fraction of patients overtreated or undertreated. LÄS MER
5. lmprovement of 177Lu-octreotate treatment of small-intestine neuroendocrine tumors by hyperfractionation
Sammanfattning : Neuroendocrine tumor incidence is steadily rising, and the late diagnosis often results in metastatic disease and current treatments mostly prolong life and in-crease quality of life without increasing cure rate. 177Lu-octreotate was recently approved for treatment of neuroendocrine tumors, but the dosage scheme should be optimized. LÄS MER